Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Analysts warn that these tariffs could lead to higher production costs, reduced profitability, and even drug shortages. As Trump’s tariff threats loom, investors are left questioning whether to hold ...

Amgen (AMGN) closed at $311.55 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 0.55%. Elsewhere, the Dow gained 1.01%, while ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%.